A Multicenter, Postmarketing Study to Evaluate the Concentration of Certolizumab Pegol in the Breast Milk of Mothers Receiving Treatment With Cimzia (Certolizumab Pegol)

Trial Profile

A Multicenter, Postmarketing Study to Evaluate the Concentration of Certolizumab Pegol in the Breast Milk of Mothers Receiving Treatment With Cimzia (Certolizumab Pegol)

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Mar 2018

At a glance

  • Drugs Certolizumab pegol (Primary)
  • Indications Ankylosing spondylitis; Crohn's disease; Psoriatic arthritis; Rheumatoid arthritis; Spondylitis
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms CRADLE
  • Sponsors UCB
  • Most Recent Events

    • 22 Mar 2018 Results published in UCB the Media Release
    • 22 Mar 2018 According to an UCB media release, The approval of the CIMZIA label update is based on data from the post-marketing pharmacokinetic CRIB and CRADLE studies
    • 14 Sep 2017 According to an UCB media release, data from the study were presented at the 26th European Academy of Dermatology and Venereology (EADV) Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top